Biologics Summit Explores “The Value Proposition”
Languishing in a hospital bed after surgery for life-threatening Crohn’s disease, San Diego Chargers’ Rolf Benirschke, dangerously underweight and saddled with ostomy bags at only 24 years old, couldn’t see the value of going on.
New “Fast Facts” Scrutinizes ICER
Policymakers, providers and patients all feel the impact of The Institute for Clinical and Economic Review, whose ubiquitous cost-effectiveness reports can determine patients’ access to medicine.
What Heart Patients’ Experience Teaches Us about Pharmacy Benefit Managers
On April 9, a congressional hearing will explore the impact of pharmacy benefit managers on high drug prices.
New Hope, New Challenges for Moms with Postpartum Depression
A newly approved medication for postpartum depression could mark a major advance for new mothers – if they can access the drug.
Dignity & Dose Reduction
It’s hard to put a price on dignity. Just ask a patient dealing with PBA, or pseudobulbar affect.
What I Wish I’d Known about Gout & Kidney Disease
March is National Kidney Month, a time for advocates, health care providers, patients and their families to raise awareness about kidney health and kidney disease.
What EU Parliamentary Candidates Need to Know about Heart Health
As the European Union edges toward parliamentary elections, patient advocates have a message for candidates: Prioritize heart health.
Out-of-Pocket Costs Are Pushing Patients to the Brink
It happened again just last week. A patient cried as she explained to me that she can’t afford the out-of-pocket cost of her medicine.
Health Plans Explore Direct-to-Patient Drug Discounts
“A risk worth taking.” That’s how insurance giant United Healthcare describes requiring new employer health plans to pass drug discounts directly to their beneficiaries.
IfPA Report Card: Health Plans Reject 1 in 3 High-Risk Heart Patients
Suffered a heart attack? Diagnosed with cardiovascular disease? Confirmed you have genetic high cholesterol? None of that may matter to your health plan. As new data reveals, insurers are still saying “no” to patients whose physicians prescribe a cholesterol-lowering PCSK9 inhibitor. Even one in three at-risk patients who meet traditional criteria for coverage. […]
